HUS program (Lakewood Amedex)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameHUS program (Lakewood Amedex)
Drug Alias NameHUS-MAbSTEC human monoclonal antibody (Lakewood Amedex/Tufts)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHemolytic-Uremic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTufts University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLakewood-Amedex Inc
Active IndicationsN/A
Inactive IndicationsHemolytic-Uremic Syndrome

Other Information

ATC CodeN/A
Related LinksN/A